Business Wire

In Competition to Discover Tomorrow’s Proteins, XPRIZE Unveils Semifinalist Teams in XPRIZE Feed the Next Billion

13.7.2021 15:00:00 EEST | Business Wire | Press release

Share

Today, XPRIZE is pleased to announce the 28 semifinalist teams moving forward in XPRIZE Feed the Next Billion. The $15 million competition, launched in December 2020, is aimed at reinventing how humanity will feed future generations by incentivizing the production of structured chicken breast or fish fillet alternatives that replicate or outperform conventional chicken and fish in access, environmental sustainability, animal welfare, nutrition and health, as well as taste and texture.

Selected by the competition’s panel of judges, the 28 semi-finalist teams were chosen based on their technical submissions and represent 14 countries.

Over the next year, semifinalists will work closely with the competition’s ecosystem and sponsors, which include ASPIRE and The Tony Robbins Foundation, as they begin to develop the first iteration of their products. From the Semifinalist teams, up to 10 Finalist teams will be chosen based on the merit of their technical solution prototypes towards the end of 2022 and will split a milestone award of $2.5 million. Finalist teams will enter one last round of solution development before final judging which will award one grand prize team a prize of $7 million, second & third place prizes of $2 and $1 million respectively, and a bonus prize of $2 million. The winning teams will need to create at least twenty-five cuts of structured chicken breast or fish fillet analogs of 115 gram or four ounce that replicate the sensory properties, versatility, and nutritional profile of conventional chicken or fish.

XPRIZE is pleased to share that the following teams have been selected to move forward in the competition:

“Over the past several years, as our global population continues to grow and the demand for meat products increases, it has become clear that our current global food chain cannot keep up,” said Caroline Kolta, XPRIZE Feed the Next Billion Program Lead. “We know we need more nutritious, environmentally-friendly and sustainable alternatives to conventional animal-based products, and that wide scale adoption will require additional innovation continuously being brought to market. I am thrilled about the international cohort of Semifinalists selected to embark on this journey of innovation and exploration to shape a future of food, starting with chicken and fish.”

The XPRIZE Feed the Next Billion judging panel consists of a diverse, international group of tech industry experts working at the highest levels of academia and research. The 8 judges include:

  • Amy C. Rowat, Associate Professor of Integrative Biology and Physiology at the University of California, Los Angeles
  • Brian Jacobson, Assistant Director of Pilot Plant Operations University of Illinois, Integrated Bioprocessing Research Laboratory (IBRL)
  • Dan Blaustein-Rejto, Director of Food & Agriculture at The Breakthrough Institute
  • Kantha Shelke, Ph.D., Founder and Principal at Corvus Blue LLC
  • Dr. Keith Cox, Co-founder and Chief Scientific Officer of Seafood Analytics, Assistant Professor of Marine Fisheries at The University of Alaska Southeast (UAS)
  • Dr. Laura Domigan, Biomaterials Scientist, University of Auckland, New Zealand
  • Dr. Marcos Sanchez-Plata, Associate Professor, Global Food Security - Animal and Food Sciences at Texas Tech University
  • Olivia Ogilvie, Postdoctoral Fellowship in Cellular Agriculture with a Specific Focus on Cultured Meat - The University of Auckland

XPRIZE Feed the Next Billion originated from the Future of Food Impact Roadmap, an in-depth analysis by XPRIZE of global food system challenges, which found alternative proteins at-scale to be a critical impact area requiring significant technological advances, decreased price points, and notable shifts in consumers’ preferences. The competition was then launched with the support of partners including ASPIRE, a part of Abu Dhabi’s Advanced Technology Research Council (ATRC), the technology programme management pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) which shapes research and development for transformative technology outcomes and defines Abu Dhabi’s R&D strategy, The Tony Robbins Foundation, The Good Food Institute, Foundation for Food and Agriculture, District 3, New Harvest, and Proveg International. Through the development of chicken and fish alternatives, teams competing in the prize will work to ensure that, as the world grows in wealth, the availability of sustainable food can meet the coming demand for food products that allow the next billion to live active and healthy lives.

To learn more about XPRIZE Feed the Next Billion, visit xprize.org/feed.

ABOUT XPRIZE

XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million Rainforest XPRIZE, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1M Digital Learning Challenge. For more information, visit xprize.org.

About ASPIRE

ASPIRE drives the creation of future transformative technologies as the programme management pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC). ATRC is responsible for defining Abu Dhabi’s research and development strategy, consolidating funds for efficient investment and driving policy and regulation. ASPIRE works in consultation with cross-sector industry stakeholders, universities and research institutes to frame problem statements. It also launches grand challenges and international competitions to solve some of the world’s most pressing issues. ASPIRE brings together exceptional people, ideas, resources and technologies to solve complex challenges. For more information, please visit www.aspireuae.ae.

Connect with us on social media:

LinkedIn

Twitter

Instagram

ABOUT THE TONY ROBBINS FOUNDATION

Founded in 1991, The Tony Robbins Foundation is a nonprofit organization created to empower individuals and organizations to make a significant difference in the quality of life of people often forgotten. Through global programs and initiatives, The Tony Robbins Foundation is dedicated to creating positive changes in the lives of youth, seniors, the hungry, homeless and the imprisoned population. The Foundation helps provide millions of meals globally each year, has awarded over 2,000 grants and other resources to health and human services organizations, implemented curriculum in 1,700 plus correctional facilities and gathered thousands of young leaders from around the world with its teen programs. For more information, visit www.thetonyrobbinsfoundation.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caden Kinard, 949-280-0182
caden.kinard@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye